Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

A large body of research publications covering hematological disorders, such as acute myeloid leukemia (AML) and multiple ...

Targeted panel-based tumor mutation burden (TMB) assays are widely employed to guide immunotherapy for patients with solid tumors. However, the accuracy and consistency of this method can be ...

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with early detection critical for improving clinical outcomes. In Denmark’s CRC screening program, ...

Post-progression therapies and outcomes for patients with advanced, BRCA-related pancreatic cancer after receipt of PARP inhibitors: A national retrospective cohort study. This is an ASCO Meeting ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

Artificial Intelligence (AI) has become a potent tool in identifying genetic mutations. By leveraging AI capabilities, scientists can rapidly and accurately analyze vast amounts of data. This ...

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement ...

Against this backdrop, a team led by Professor Zhang Han and Associate Professor Chen Zhi from Shenzhen University in China , has demonstrated an innovative approach that combines DNA origami, CRISPR ...

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer Patients received (1:1) either olaparib (300 mg twice a day) or placebo ...

Proteogenomics explores how genetic information translates into protein expression and function, and the role of changes across DNA, RNA, and proteins in influencing disease development and ...

Agilus Diagnostics launches Idylla system to deliver cancer mutation results in just 3 hours: Our Bureau, Mumbai Tuesday, ...